These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9183312)

  • 21. Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep vein thrombosis.
    Kim TW; Kim WK; Lee JH; Kim SB; Kim SW; Suh C; Lee KH; Lee JS; Seo EJ; Chi HS; Kim SH
    J Korean Med Sci; 1998 Dec; 13(6):587-90. PubMed ID: 9886165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Activated protein C resistance, Leiden mutation, anticoagulant proteins and fibrinogen levels in patients with deep venous thrombosis].
    Jastrzebska M; Bałszan-Kowalska I; Ciechanowicz A; Bińczak-Kuleta A; Falkowski A; Chełstowski K
    Pol Arch Med Wewn; 2003 Jun; 109(6):579-88. PubMed ID: 14567090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Point mutation G-->A nucleotide 1691 factor V gene as a cause of developing thrombotic complications in a family with plasma resistance to activated protein C].
    Lew Andowski KL; Rozek M; Turowiecka Z; Markiewicz WT; Zawilska K
    Pol Arch Med Wewn; 1996 May; 95(5):464-70. PubMed ID: 8848415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of factor V Leiden in children with thrombo-embolism.
    Aschka I; Aumann V; Bergmann F; Budde U; Eberl W; Eckhof-Donovan S; Krey S; Nowak-Göttl U; Schobess R; Sutor AH; Wendisch J; Schneppenheim R
    Eur J Pediatr; 1996 Dec; 155(12):1009-14. PubMed ID: 8956934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese.
    Irani-Hakime N; Tamim H; Kreidy R; Almawi WY
    Am J Hematol; 2000 Sep; 65(1):45-9. PubMed ID: 10936863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factor V gene mutation causing inherited resistance to activated protein C as a basis for venous thromboembolism.
    Dahlbäck B
    J Intern Med; 1995 Mar; 237(3):221-7. PubMed ID: 7891043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance).
    Rosendaal FR; Koster T; Vandenbroucke JP; Reitsma PH
    Blood; 1995 Mar; 85(6):1504-8. PubMed ID: 7888671
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Resistance to activated protein C in venous thromboembolic complications. Incidence and clinical manifestations].
    Trossaërt M; Conard J; Horellou MH; Samaha M; Elalamy I; Samama MM
    Presse Med; 1995 Jan; 24(4):209-12. PubMed ID: 7899365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factor V R506Q gene mutation analysis by PCR-RFLP: optimization, comparison with functional testing for resistance to activated protein C, and establishment of cell line controls.
    Voelkerding KV; Wu L; Williams EC; Hoffman SM; Sabatini LM; Borcherding WR; Huber S
    Am J Clin Pathol; 1996 Jul; 106(1):100-6. PubMed ID: 8701917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
    Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
    Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.
    Heinemann LA; Assmann A; Spannagl M; Schramm W; Dick A; Kluft C; de Maat MP
    Contraception; 1998 Nov; 58(5):321-2. PubMed ID: 9883389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lupus anticoagulant interference in activated protein C resistance testing: in vitro phenomenon or in vivo pathophysiologic effect?
    Shen YM; Cimo ML; Bai Y; Frenkel E; Sarode R
    Clin Appl Thromb Hemost; 2011; 17(6):E190-5. PubMed ID: 21406411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population].
    Ehrenforth S; Klinke S; von Depka Prondzinski M; Kreuz W; Ganser A; Scharrer I
    Dtsch Med Wochenschr; 1999 Jun; 124(25-26):783-7. PubMed ID: 10414227
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls.
    Svensson PJ; Zöller B; Dahlbäck B
    Thromb Haemost; 1997 Feb; 77(2):332-5. PubMed ID: 9157592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The 1691 G-->A mutation in the factor V gene: relationship to activated protein C (APC) resistance and thrombosis in 65 patients.
    Leroy-Matheron C; Levent M; Pignon JM; Mendonça C; Gouault-Heilmann M
    Thromb Haemost; 1996 Jan; 75(1):4-10. PubMed ID: 8713771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factor V Leiden mutation is not increased in patients with inflammatory bowel disease.
    Zauber NP; Sabbath-Solitare M; Rajoria G; Mogan G
    J Clin Gastroenterol; 1998 Oct; 27(3):215-6. PubMed ID: 9802448
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prevalence of Factor V Leiden and the G20210A mutation of the prothrombin gene in a random group of patients with thrombotic episodes].
    Alvarez A; Barroso A; Robledo M; Arranz E; Outeiriño J; Benítez J
    Sangre (Barc); 1999 Feb; 44(1):7-12. PubMed ID: 10323090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sensitivity and specificity of the APC resistance assay in detection of individuals with factor V Leiden.
    Zehnder JL; Benson RC
    Am J Clin Pathol; 1996 Jul; 106(1):107-11. PubMed ID: 8701918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of activated protein C resistance (Factor V Leiden) in Lagos, Nigeria.
    Adeyemo TA; Adediran A; Akinbami AA; Akanmu AS
    Niger J Clin Pract; 2012; 15(2):136-41. PubMed ID: 22718159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnosis strategies in activated protein C resistance: is genotyping still necessary?
    Biron C; Lamarti H; Schved JF; Jeanjean P; Masmejean C; Claustres M; Aguilar-Martinez P
    Clin Lab Haematol; 1997 Mar; 19(1):67-71. PubMed ID: 9146951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.